You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back


Active ingredients of Incruse Ellipta 1

Incruse Ellipta 55 mcg (umeclidinium) inhalation powder.

Each single inhalation provides a delivered dose (the dose leaving the mouthpiece of the inhaler) of 55 micrograms (mcg) umeclidinium (equivalent to 65 mcg of umeclidinium bromide). This corresponds to a pre-dispensed dose of 62.5 mcg umeclidinium equivalent to 74.2 mcg umeclidinium bromide.

Incruse Ellipta Indication:

Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 1


  1. Incruse Ellipta 55 mcg SPC; GlaxoSmithKline

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Incruse and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies